Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | 134,000 |
| Gross Profit (TTM) | 111,000 |
| EBITDA | $-19.62M |
| Operating Margin | -13740.00% |
| Return on Equity | -1738.00% |
| Return on Assets | -56.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-1.60 |
| Price-to-Book | 7.83 |
| Price-to-Sales (TTM) | 638.92 |
| EV/Revenue | 754.36 |
| EV/EBITDA | -1.13 |
| Quarterly Earnings Growth (YoY) | 61.40% |
| Quarterly Revenue Growth (YoY) | -81.50% |
| Shares Outstanding | $12.78M |
| Float | $10.43M |
| % Insiders | 24.56% |
| % Institutions | 22.43% |
Volatility is currently contracting